La chaîne d'options affiche les données clés des options sur actions de SciSparc à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour SciSparc..

SciSparc (NASDAQ:SPRC) Stock, Chaîne d'Options

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

SciSparc Ltd

Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) has outperformed the market over the past 20 years by 4.63% on an annualized basis producing an average annual return of 12.91%. Currently, Applied Industrial Techs has a market capitalization of $8.91 billion. 
Buying $100 In AIT: If an investor had bought $100 of AIT stock 20 years ago, it would be worth $1,157.94 today based on a price of $232.10 for AIT at the time of writing.
<h3>Applied Industrial Techs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747241213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Scott Buck reiterates Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) with a Buy and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

MOGO

HC Wainwright & Co. Reiterates Buy on Mogo, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede downgrades WonderFi Techs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WNDR#TSX">WNDR</a>) from Buy to Neutral.

Downgrades

TSX:WNDR

HC Wainwright & Co. Downgrades WonderFi Techs to Neutral

WIIM

Sanofi share are trading lower after the company announced plans to invest at least $20 billion in the US through 2030.

PONY

Pony AI shares are trading lower. CNBC reported that one of the company's robotaxis caught fire.

Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing.
The announcement comes as Sanofi prepares for the potential launch of numerous new first- or best-in-class medicines across many indications in the coming years, aiming to improve the health of countless Americans. Work being done within the United States by Sanofi and by the hundreds of companies it supports is anticipated to contribute to job creation and innovation in numerous communities that are home to Sanofi and its partners, while also helping to enhance the US supply chain.

Sanofi Intends To Invest At Least $20B In US Through 2030, Growing Investments In Science And Expanding Domestic Manufacturing

ARAI

Arrive AI Receives Approval To List Its Shares On Nasdaq Under Symbol ARAI; To Begin Trading On May 15, 2025

Needham analyst Ryan Koontz reiterates Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and maintains $8 price target.

Needham Reiterates Buy on Planet Labs, Maintains $8 Price Target

V2X Collaborates With Bell Textron To Begin Strategic Planning For U.S. Army's Flight School Next Program

Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) has outperformed the market over the past 5 years by 1.87% on an annualized basis producing an average annual return of 16.9%. Currently, Fidelity National Finl has a market capitalization of $15.60 billion. 
Buying $100 In FNF: If an investor had bought $100 of FNF stock 5 years ago, it would be worth $215.81 today based on a price of $56.79 for FNF at the time of writing.
<h3>Fidelity National Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747240311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Fidelity National Finl 5 Years Ago Would Be Worth Today

VRTX

Live On CNBC, Steve Weiss Announces Sold Vertex Pharmaceuticals

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) with a Market Perform and raises the price target from $38 to $40.

NYAX

Keefe, Bruyette & Woods Maintains Market Perform on Nayax, Raises Price Target to $40

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL</a>.

Biotech

General

Reported Earlier: 'FDA Approves Belzutifan For Pheochromocytoma Or Paraganglioma' - FDA

BMO Capital analyst Simeon Siegel maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Outperform and lowers the price target from $12 to $9.

BMO Capital Maintains Outperform on Under Armour, Lowers Price Target to $9

CAE shares are trading lower after the company reported mixed Q4 financial results.

<a href="https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur" title="https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur">https://www.bleeckerstreetresearch.com/research/aurora-innovation-aur</a>

Short Sellers

Watching Aurora Innovation; Bleecker Street Research Issues Report On Co

BMO Capital analyst Simeon Siegel maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Market Perform and lowers the price target from $15 to $11.

BMO Capital Maintains Market Perform on American Eagle Outfitters, Lowers Price Target to $11

BMO Capital analyst Keith Bachman maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Market Perform and raises the price target from $130 to $135.

OKTA

BMO Capital Maintains Market Perform on Okta, Raises Price Target to $135

BMO Capital analyst James Thalacker maintains NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) with a Market Perform and raises the price target from $115 to $167.

BMO Capital Maintains Market Perform on NRG Energy, Raises Price Target to $167

Press Releases

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Contracts

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Health Care

Legal

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Bulls Turn to Pennies STSS, ADTX, CSDX, SPRC, CBDW, YGTFF During Market Uncertainty – Small-Cap Stocks Poised for Big Moves

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Comments

SciSparc

SciSparc (SPRC) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL